Alps Advisors Inc. Makes New $447,000 Investment in TransMedics Group, Inc. $TMDX

Alps Advisors Inc. purchased a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 3,980 shares of the company’s stock, valued at approximately $447,000.

A number of other large investors also recently modified their holdings of the business. Marshall Wace LLP lifted its holdings in shares of TransMedics Group by 258.7% in the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock valued at $73,275,000 after buying an additional 394,340 shares during the period. Zevenbergen Capital Investments LLC boosted its holdings in TransMedics Group by 112.7% in the third quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock worth $29,006,000 after purchasing an additional 136,995 shares in the last quarter. Next Century Growth Investors LLC bought a new stake in shares of TransMedics Group during the 2nd quarter worth $16,049,000. Goldman Sachs Group Inc. grew its stake in shares of TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after acquiring an additional 86,721 shares during the last quarter. Finally, Renaissance Group LLC bought a new position in shares of TransMedics Group during the 3rd quarter worth about $8,536,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $129.84 on Friday. The stock has a market cap of $4.44 billion, a price-to-earnings ratio of 52.57 and a beta of 2.06. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The firm’s 50-day simple moving average is $132.32 and its 200 day simple moving average is $125.42. TransMedics Group, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $156.00.

Analyst Ratings Changes

TMDX has been the topic of several analyst reports. Needham & Company LLC upped their target price on shares of TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Canaccord Genuity Group increased their target price on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Morgan Stanley raised their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Finally, Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.25.

Insider Buying and Selling at TransMedics Group

In related news, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the transaction, the chief financial officer owned 15,064 shares in the company, valued at approximately $2,103,235.68. This represents a 5.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anil P. Ranganath sold 3,000 shares of TransMedics Group stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the sale, the insider directly owned 13,955 shares in the company, valued at approximately $2,026,545.10. This represents a 17.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 8,920 shares of company stock worth $1,257,310 in the last quarter. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.